Last updated on February 2019

Phase 2a Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)


Brief description of study

Phase 2a, dose-ranging Study with PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)

Detailed Study Description

A Phase 2a, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Study To Evaluate Safety, Tolerability, And Pharmacodynamics Of PF-05221304 Administered Daily For 16-weeks To Adult Subjects With Nonalcoholic Fatty Liver Disease

Clinical Study Identifier: NCT03248882

Contact Investigators or Research Sites near you

Start Over

Pfizer CT.gov Call Center

Flinders Medical Centre/Department of Gastroenterology & Hepatology
Adelaide, Australia
1.81miles
  Connect »

Pfizer CT.gov Call Center

Dr. Jones & Partners Medical Imaging
Adelaide, Australia
3.45miles
  Connect »

Pfizer CT.gov Call Center

Royal Adelaide Hospital, Department of Gastroenterology and Hepatology
Adelaide, Australia
3.45miles
  Connect »

Pfizer CT.gov Call Center

Radiology SA
Adelaide, Australia
4.66miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.